<DOC>
	<DOCNO>NCT02264288</DOCNO>
	<brief_summary>The PDA-002-DFU-002 trial Phase 2 , multicenter , randomize , double blind , placebo control , dose range find study . The study enroll approximately 133 subject four treatment group . The primary objective study assess efficacy safety PDA-002 administer intramuscular ( IM ) subject DFU without PAD . The secondary objective explore potential clinical efficacy assess change vascular parameter Ankle-Brachial Index Toe-Brachial Index ( ABI and/or TBI ) , Transcutaneous oxygen measurement ( TcPO2 ) .</brief_summary>
	<brief_title>Efficacy Safety Intramuscular PDA-002 Subjects Who Have Diabetic Foot Ulcer With Without Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Males female , least 18 year age old time signing informed consent document . 2 . Understand voluntarily sign informed consent document prior study related assessments/procedures conduct . 3 . Able adhere study visit schedule protocol requirement . 4 . Diabetes mellitus Type 1 Type 2 . 5 . Diabetic foot ulcer severity Grade 1 ( full thickness ) Grade 2 Wagner Grading Scale ( Appendix A ) great one month duration adequately respond conventional ulcer therapy size least 1cm2 except present toe . The maximum lesion size range index ulcer ≤ 10cm2 . The measurement index ulcer evaluate measure debridement ( necessary ) Screening Visit . If locate plantar aspect foot , index ulcer must able adequately offloaded assessment investigator . 6 . No planned revascularization amputation next 3 month Screening visit , opinion Investigator . 7 . Screening begin least 14 day fail reperfusion intervention least 30 day successful reperfusion intervention . 8 . Subjects receive appropriate medical therapy hypertension diabetes chronic medical condition require ongoing care . 9 . A female childbearing potential must negative serum pregnancy test Screening negative urine pregnancy test prior treatment study therapy . In addition , sexually active FCBP must agree use 2 follow adequate form contraception method simultaneously : oral , injectable , implantable hormonal contraception ; tubal ligation ; IUD ; barrier contraceptive spermicide vasectomize partner duration study Followup Period . 10 . Males ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage reproductive sexual activity FCBP duration study Followup Period . 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Any condition include presence laboratory abnormality , place subject unacceptable risk participate study . 3 . Any condition confound ability interpret data study . 4 . Pregnant lactating female . 5 . Subjects body mass index &gt; 45 kg/m2 Screening . 6 . AST ( SGOT ) ALT ( SGPT ) &gt; 2.5 x upper limit normal ( ULN ) Screening . 7 . Patient renal dialysis abnormal kidney function . 8 . An ABI &lt; 0.4 TBI &lt; 0.3 leg index ulcer . 9 . Bilirubin level &gt; 2 mg/dL ( unless subject know Gilbert 's disease ) Screening . 10 . Untreated chronic infection treatment infection systemic antibiotic , include ulcer site , must free antibiotic within 1 week prior dose IP . 11 . Active osteomyelitis , infection , cellulites adjacent index ulcer . Patients history treat osteomyelitis without surgical resection . 12 . Index ulcer decrease increase size ≥ 30 % Screening/RunIn/ PreTreatment Period . 13 . Active Charcot Neuroarthropathy foot index ulcer 14 . Pain rest due limb ischemia . 15 . Uncontrolled hypertension ( define diastolic blood pressure &gt; 100 mmHg systolic blood pressure &gt; 180 mmHg Screening 2 independent measurement take subject sit rest least 5 minute ) . 16 . Poorly control diabetes mellitus ( hemoglobin A1c &gt; 12 % screen serum glucose ≥ 300mg/dl ) . 17 . Untreated proliferative retinopathy . 18 . History malignant ventricular arrhythmia , CCS Class IIIIV angina pectoris , myocardial infarction/ percutaneous coronary intervention ( PCI ) / coronary artery bypass graft ( CABG ) precede 6 month prior sign inform consent form ( ICF ) , pending coronary revascularization follow 3 month , transient ischemic attack/cerebrovascular accident precede 6 month , prior sign ICF , and/or New York Heart Association [ NYHA ] Stage III IV congestive heart failure . 19 . Abnormal ECG : new right bundle branch block ( BBB ) ≥ 120 msec precede 3 month prior sign ICF . 20 . Uncontrolled hypercoagulation syndrome . 21 . Life expectancy le 2 year time sign ICF due concomitant illness . 22 . In opinion Investigator , subject unsuitable cellular therapy . 23 . History malignancy within 5 year prior sign ICF except basal cell squamous cell carcinoma skin remote history cancer consider cure positive Pap smear subsequent negative followup . 24 . History hypersensitivity component product formulation ( include bovine porcine product , dextran 40 , dimethyl sulfoxide [ DMSO ] ) . 25 . Subject receive investigational agent —an agent device approve US Food Drug Administration ( FDA ) market use indication— within 90 day ( 5 halflives , whichever long ) prior treatment study therapy plan participation another therapeutic study prior completion study . 26 . Subject receive previous investigational gene cell therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Diabetic Foot</keyword>
</DOC>